Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1

Aclaris Therapeutics (ACRS) Halted, News Pending

October 24, 2019 4:00 PM EDT

Aclaris Therapeutics (NASDAQ: ACRS) Halted, News Pending

... More

Pre-Open 10/22: (BIIB) (STMP) (GNC) Higher (TTS) (TEUM) (HHC) Lower (more...)

October 22, 2019 9:30 AM EDT

Today's Pre-Open Movers

Tile Shop (NASDAQ: TTS) 71% LOWER; reported Q3 EPS of ($0.03), $0.03 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $85.94 million versus the consensus estimate of $85.91 million. To suspend dividend, cancel buyback. To delist from NASDAQ.

Pareteum Corporation (Nasdaq: TEUM) 48.1% LOWER; announced that the Company will restate its previously issued consolidated financial statements as of and for the full year... More

UPDATE: SVB Leerink Upgrades Aclaris Therapeutis (ACRS) to Outperform; More than Doubles Price Target

October 22, 2019 6:37 AM EDT

(Updated - October 22, 2019 9:15 AM EDT)

(updated to add analyst comments)

SVB Leerink analyst Pasha Sarraf upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Market Perform to Outperform and raises their price target to $3.50 (from $1.50).

ACRS has now chosen to focus... More